Targeted Treatment of HR+/HER2-Breast Cancer

Medical experts discuss several topics pertaining to the evolving treatments in HR+/HER2- advanced breast cancer, including unmet needs and the integral role of pharmacists in patient care.

EP. 1: Disease Factors Influencing Treatment Pathways For HR+/HER2- Advanced Breast Cancer

June 30th 2022

Dr Ryan Haumschild, PharmD, MS, MBA, leads a discussion focused on HR-positive, HER2-negative treatment in advanced-stage breast cancer.

EP. 2: Successful Clinical Outcomes With Treatment in Advanced-Stage Breast Cancer

June 30th 2022

Heather N. Moore, PharmD, BCOP, CPP, and Susan Faye Dent, MD, FRCPC, FICQS, emphasize the critical role of the pharmacist in achieving clinical endpoints in advanced-stage breast cancer.